/
LUNG
$2.24+$0.08 (+3.70%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$98.4M
43M shares
52-week range
$1.13 – $2.89
63% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Change$-35.13
Pulmonx Corporation Common Stock
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
www.pulmonx.com- Employees
- 296
- IPO / List date
- Oct 1, 2020
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds LUNG.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 320,300 | $413.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LUNG yet.
